RxDoctor Payments Data

Daniel Karn, PA

Physician Assistant · Moravia, NYNPI 1619973575

Payments from drug & device makers

$869in general payments, 2019–2025

Across 49 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$327
  • AbbVie$229
  • Novo Nordisk$94
  • GSK$68
  • Amarin Pharma, Inc.$44
  • Lilly USA, LLC$31
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$869100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$869 in reported general payments places this provider in the 70th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$247
Medicare patients
21
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide106$150,293
EliquisApixaban68$81,575
JardianceEmpagliflozin65$81,275
XareltoRivaroxaban27$40,896
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$37,013
FarxigaDapagliflozin Propanediol21$33,105
OzempicSemaglutide25$29,291
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$27,065
RybelsusSemaglutide11$27,039
JanuviaSitagliptin Phosphate14$21,616
MyrbetriqMirabegron15$14,594
Incruse ElliptaUmeclidinium Bromide21$11,955
Spiriva RespimatTiotropium Bromide14$9,231
Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro12$7,237
Albuterol Sulfate HfaAlbuterol Sulfate210$6,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$31$150,293106 claims
Boehringer IngelheimJardiance, Spiriva Respimat$12$90,50679 claims
PfizerEliquis$28$81,57568 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$68$76,03288 claims
Novo NordiskOzempic, Rybelsus$94$56,33036 claims
AstraZenecaFarxiga, Symbicort$327$38,40032 claims
AbbVieSynthroid$229$1,36316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Moravia

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →